Merit Medical Announces Increased Sales and Improved Earnings


SOUTH JORDAN, Utah, May 2, 2007 (PRIME NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology and radiology procedures, today announced revenues of $51.0 million for the first quarter ended March 31, 2007, an increase of 13.3% over revenues of $45.0 million for the first quarter of 2006.

Net income for the first quarter of 2007 improved 24% to $3.0 million, or $0.10 per share, from $2.4 million, or $0.09 per share, for the first quarter of 2006.

"We are pleased with our sales performance for the first quarter, especially following the 19% increase for the fourth quarter of 2006," said Fred P. Lampropoulos, Merit's Chairman and CEO. "We are also pleased to see the improvement in earnings, which was our first sequential improvement in 11 quarters."

"Parts of our company improvement plan are starting to take effect," Lampropoulos continued. "If we exclude the $800,000 of inventory we acquired from Datascope, our inventory for the first quarter of 2007 would have dropped approximately $400,000 from the fourth quarter of 2006, which is the first inventory reduction in almost four years. We expect continued improvement in inventories and gross margins as we become more efficient through cost savings programs from automation and the movement of high-labor products to offshore contract manufacturing.

"Additionally, we expect to introduce several new, high-margin product lines in the next few months," Lampropoulos added. "The new 'Meritized' version of the acquired chronic dialysis catheter has been designed to include all the products necessary for initial or exchange procedures, including several of Merit's patented products."

All product categories of Merit's business contributed to revenue growth in the first quarter of 2007, with stand-alone device sales increasing 20%; catheter sales rising 18%; custom kit and tray sales growing 18%; and inflation device sales increasing 1%.

Gross margins for the first quarter of 2007 were 37.0% of sales, compared to 37.9% of sales for the first quarter of 2006. The decrease in gross margins for the first quarter of 2007 can be attributed primarily to an increase in wages beginning in the fourth quarter of 2006, additional headcount, higher health benefit costs, and increases in depreciation of new production equipment.

Selling, general and administrative expenses for the first quarter of 2007 were 23.5% of sales, compared to 25.0% of sales for the first quarter of 2006. Research and development costs during both the first quarter of 2007 and the first quarter of 2006 were 4.6% of sales.

Income from operations for the quarter ended March 31, 2007 was $4.5 million, compared to $3.7 million for the same period in 2006.

Merit's effective tax rate for the first quarter of 2007 was 35.0%, compared with 36.0% for the comparable period of 2006.

The Company's cash position was $9.6 million on March 31, 2007, compared with $9.8 million on December 31, 2006. The Company's current cash position is net of a recent $3.0 million acquisition of a new dialysis catheter from Datascope.

CONFERENCE CALL

Merit Medical invites all interested parties to participate in its conference call today, May 2, at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). The domestic phone number is 800-257-7087, and the international number is 303-262-2125. A live webcast as well as a rebroadcast can be accessed through the webcast tab of the Investors page at www.merit.com or through the webcasts tab at www.fulldisclosure.com.



 INCOME STATEMENT
 (Unaudited, in thousands except per share data)

                                                  Three Months Ended
                                                      March 31,
                                              ------------------------
                                                 2007          2006
                                              ----------    ----------

 SALES                                        $   51,030    $   45,040

 COST OF SALES                                    32,172        27,990
                                              ----------    ----------

 GROSS PROFIT                                     18,858        17,050

 OPERATING EXPENSES
 Selling, general and administrative              12,015        11,238
 Research and development                          2,364         2,078
                                              ----------    ----------
 Total                                            14,379        13,316

 INCOME FROM OPERATIONS                            4,479         3,734

 OTHER INCOME (EXPENSE)
 Interest income                                      89            46
 Other income (expense)                               (1)          (28)
                                              ----------    ----------
 Total Other Income - net                             88            18

 INCOME BEFORE INCOME TAXES                        4,567         3,752

 INCOME TAX EXPENSE                                1,598         1,351
                                              ----------    ----------

 NET INCOME                                   $    2,969    $    2,401
                                              ----------    ----------

 EARNINGS PER COMMON SHARE-
  Basic                                       $     0.11    $     0.09
                                              ==========    ==========
  Diluted                                     $     0.10    $     0.09
                                              ==========    ==========

 AVERAGE COMMON SHARES-
  Basic                                       27,652,971    27,195,671
                                              ==========    ==========

  Diluted                                     28,616,595    28,092,099
                                              ==========    ==========



 BALANCE SHEET
 (Unaudited in thousands)

                                               March 31,   December 31,
                                                 2007          2006
                                              ----------    ----------
 ASSETS

 Current Assets

 Cash and cash equivalents                    $    9,645    $    9,838
 Trade receivables, net                           25,986        25,745
 Employee receivables                                183           194
 Other receivables                                   457           192
 Inventories                                      38,960        38,562
 Prepaid expenses and other assets                 1,241         1,031
 Deferred income tax assets                            3             2
 Income tax refunds receivable                        81            82
                                              ----------    ----------
 Total Current Assets                             76,556        75,646

 Property and equipment, net                      95,421        92,383
 Other intangibles, net                            4,705         4,350
 Goodwill                                          9,684         7,541
 Other assets                                      2,830         2,656
 Deferred income tax assets                            3             2
 Deposits                                             84            90
                                              ----------    ----------
 Total Assets                                 $  189,283    $  182,668
                                              ==========    ==========

 LIABILITIES AND STOCKHOLDERS' EQUITY

 Current Liabilities

 Trade payables                                   11,818        10,598
 Accrued expenses                                  8,684         8,464
 Advances from employees                             232           245
 Deferred income tax liabilities                      75           190
 Income taxes payable                              1,252         1,177
                                              ----------    ----------
  Total Current Liabilities                       22,061        20,674

 Deferred income tax liabilities                   5,467         5,469
 Liabilities related to unrecognized
   tax positions                                   1,901
 Deferred compensation payable                     2,950         2,869
 Deferred credits                                  2,200         2,239
 Other long-term obligation                          178           205
                                              ----------    ----------
  Total Liabilities                               34,757        31,456

 Stockholders' Equity

 Common stock                                     55,336        54,394
 Retained earnings                                99,329        96,969
 Accumulated other comprehensive loss               (139)         (151)
                                              ----------    ----------
  Total stockholders' equity                     154,526       151,212
                                              ----------    ----------

 Total Liabilities and Stockholders' Equity   $  189,283    $  182,668
                                              ==========    ==========

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 85 individuals. Merit employs approximately 1,750 people worldwide, with facilities in Salt Lake City and South Jordan, Utah; Santa Clara, California; Angleton, Texas; Richmond, Virginia; Maastricht and Venlo, The Netherlands; and Galway, Ireland.

The Merit Medical Systems, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3282

Statements contained in this release, which are not purely historical, are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2006. Such risks and uncertainties include product recalls and product liability claims; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; termination of relationship with suppliers, or failure of suppliers to perform; inability to successfully manage growth through acquisitions; delays in obtaining regulatory approvals, or the failure to maintain such approvals; significant portion of our revenues are derived from a few products and procedures; development of new products and technology that could render Merit's products obsolete, market acceptance of new products, introduction of products in a timely fashion, price and product competition, availability of labor and materials, cost increases, and fluctuations in and obsolescence of inventory; market price of our common stock has been and may continue to be volatile; foreign currency fluctuations; key personnel; work stoppage or transportation risks; modification or limitation of governmental or private insurance reimbursement, changes in health care markets related to health care reform initiatives; and other factors referred to in the Company's 10-K and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.



            

Contact Data